Company Overview
Snapshot
Founded in March 2020, MigVax operates with 1–10 employees. The company has raised $21.3M across four funding rounds from OurCrowd and Happiness Capital. In April 2020, MigVax secured an A Round of funding, with OurCrowd participating as a lead investor.
Business overview
MigVax is a Health Tech & Life Sciences company focused on developing vaccines for human viruses. The company's core technology is a sub-unit vaccine approach utilizing a chimeric protein to present viral proteins to the immune system. This method, based on a successful avian coronavirus vaccine, aims to generate mucosal, blood-based, and cell-mediated immunity. MigVax primarily operates in the Pharmaceuticals sector, specifically in Drugs Discovery & Development, with an initial focus on COVID-19.
Strategic signal
In June 2022, MigVax partnered with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19. This collaboration signals a strategic move towards innovative drug delivery methods and potentially broader market accessibility for their vaccine technology, indicating a focus on advanced formulation and patient convenience in vaccine development.
Log in to access full profile ›Company Intelligence Q&A
- What is MigVax's primary focus?
- MigVax specializes in the development of vaccines for viruses in humans, initially focusing on COVID-19, leveraging technology originally developed for an avian coronavirus.
- When was MigVax founded?
- MigVax was founded in March 2020.
- What was a significant partnership for MigVax in 2022?
- In June 2022, MigVax signed an agreement with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19.
- Which investors participated in MigVax's April 2020 funding round?
- In April 2020, MigVax received funding from OurCrowd and Happiness Capital, with OurCrowd acting as a lead investor.
- What was a key leadership change for MigVax in 2022?
- In May 2022, MigVax appointed Ran Amir as its new CEO.